United for Cures Commends Senate for NIH Funding Increases, Calls on Congress to “Finish the Job”

WASHINGTON, DC (November 16, 2026) – United for Cures, a collaborative network of 60+ patient advocacy organizations, commended the Senate Appropriations Committee for including a $500 million increase for the National Institutes of Health (NIH) and related medical research programs in its Fiscal Year (FY) 2027 Labor, Health and Human Services, Education, and Related Agencies appropriations bill.

United for Cures Executive Director Erika Sward said, “Medical research saves lives and makes our nation healthier. We appreciate the Senate Appropriations Committee’s proposed $500 million increase for NIH. Now Congress must deliver a full-year funding bill that ensures the resources needed to pursue treatments and cures are available. Patients cannot afford to wait.”

Sward urged Congress to use the full-year appropriations process to strengthen protections for federal medical research. While the current continuing resolution prevents the Office of Management and Budget (OMB) from finalizing its proposed changes to federal grantmaking regulations through December 11, 2026, that protection is temporary.

“We appreciate the bipartisan action Congress has already taken to temporarily block OMB’s proposed rule, but the underlying threat has not gone away,” said Sward. “Congress must continue protecting the integrity of federal research funding decisions and block the proposed OMB rule from taking effect.”

“As 57 leading patient advocacy organizations previously warned congressional leaders, changes that introduce greater political control over federal research grants could have far-reaching consequences for America’s leadership in biomedical research,” Sward continued. “Medical research and clinical trials can take years to complete, and once those clinical trials begin, we cannot allow the rug to be ripped out from under them if a grant is canceled for political reasons. Canceling clinical trials also results in millions of dollars of wasted federal funding. Congress must ensure that funding decisions will remain guided by scientific merit, expert review, and patient need.”

Sward also welcomed the Committee’s decision to preserve language limiting how much NIH funding can be committed upfront to multiyear research grants.

“We are grateful that once again the Committee preserved these important protections, which help ensure that more funding remains available to support new research projects and promising scientific discoveries,” said Sward. “By limiting the amount of funding committed upfront to multiyear grants, NIH can support a broader range of research opportunities and maximize the number of medical breakthroughs possible.”

Sward concluded, “Now it’s time for the 119th Congress to finish its job and deliver a full-year funding bill that keeps lifesaving medical research moving forward. A continuing resolution may provide short-term stability, but it is not a substitute for predictable funding that allows researchers to plan long-term studies, sustain clinical trials, and pursue promising discoveries. Every day matters. Patients and families cannot afford unnecessary delays in the research that brings us closer to new treatments and cures.”